Kura Oncology, Inc. (KURA) — real insider trading activity disclosed to the SEC, tracked automatically as new Form 4 filings are reported. Most recent: WILSON TROY EDWARD — 2 open-market purchases between 2026-08-17 and 2026-08-24, totaling $2,351,000.
Transactions disclosed by company insiders to the SEC on Form 4, most recent first.
| Insider | Role | Date | Shares | Value |
|---|---|---|---|---|
| FORD KATHLEEN | Chief Operating Officer | 2026-09-29 | 3,668 | $39,437 |
| Powl Brian T. | Chief Commercial Officer | 2026-09-29 | 15,430 | $165,852 |
| Leoni Mollie | Chief Medical Officer | 2026-09-29 | 28,802 | $309,567 |
| FORD KATHLEEN | Chief Operating Officer | 2026-09-28 | 6,906 | $72,494 |
| Bair Teresa Brophy | Chief Legal Officer | 2026-09-28 | 8,442 | $88,618 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | 2026-09-28 | 4,607 | $48,361 |
| Powl Brian T. | Chief Commercial Officer | 2026-09-28 | 9,020 | $94,686 |
| Powl Brian T. | Chief Commercial Officer | 2026-09-28 | 8,000 | $84,498 |
| Leoni Mollie | Chief Medical Officer | 2026-09-28 | 12,448 | $130,670 |
| Burrows Francis | Chief Scientific Officer | 2026-09-24 | 30,000 | $184,500 |
Position changes disclosed in SEC Form 13F filings. These report a quarterly snapshot, not exact trade dates.
| Fund | Change | Quarter |
|---|---|---|
| MONTANOVA CAPITAL, LLC | MONTANOVA CAPITAL, LLC increased this position by 35% ($69,718,181 -> $94,072,379). | 2026-06-30 |
| BVF INC/IL | BVF INC/IL increased this position by 35% ($68,664,102 -> $92,650,086). | 2026-06-30 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP opened a new position worth $15,470,717. | 2026-06-30 |
| RENAISSANCE TECHNOLOGIES LLC | RENAISSANCE TECHNOLOGIES LLC increased this position by 42% ($12,866,278 -> $18,251,502). | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | VANGUARD CAPITAL MANAGEMENT LLC increased this position by 40% ($30,777,619 -> $42,960,319). | 2026-06-30 |
| GOLDMAN SACHS GROUP INC | GOLDMAN SACHS GROUP INC increased this position by 117% ($9,875,934 -> $21,431,551). | 2026-06-30 |
| ALETHEA CAPITAL MANAGEMENT, LLC | ALETHEA CAPITAL MANAGEMENT, LLC increased this position by 91% ($12,433,770 -> $23,782,280). | 2026-06-30 |
| ARMISTICE CAPITAL, LLC | ARMISTICE CAPITAL, LLC increased this position by 33% ($30,373,680 -> $40,347,660). | 2026-06-30 |
Largest reported positions as of 2026-06-30.
| Fund | Value | Shares |
|---|---|---|
| MONTANOVA CAPITAL, LLC | $94,072,379 | 8,575,422 |
| BVF INC/IL | $92,650,086 | 8,445,769 |
| VANGUARD CAPITAL MANAGEMENT LLC | $42,960,319 | 3,916,164 |
| ARMISTICE CAPITAL, LLC | $40,347,660 | 3,678,000 |
| ALETHEA CAPITAL MANAGEMENT, LLC | $23,782,280 | 2,167,938 |
| Prosight Management, LP | $22,180,945 | 2,021,964 |
| Deep Track Capital, LP | $21,704,858 | 1,978,565 |
| GOLDMAN SACHS GROUP INC | $21,431,551 | 1,953,651 |
| GEODE CAPITAL MANAGEMENT, LLC | $20,956,569 | 1,909,862 |
| RENAISSANCE TECHNOLOGIES LLC | $18,251,502 | 1,663,765 |
Data compiled from public SEC filings. This is informational reporting, not investment advice.
Kura Oncology, Inc. (KURA) President and CEO Troy Edward Wilson disclosed an open-market purchase of 100,000 shares on August 24, 2026, according to a Form 4 filed with the SEC. Wilson paid $12.39 per share, spending $1,239,000.00 of his own money. Following the purchase, he holds 479,194 shares indirectly, through a trust or other entity … Read more